Piebaldism

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2884OMIM:172800E70.3
Who is this for?
Show terms as
10Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Piebaldism (also known as partial albinism or piebald trait) is a rare congenital disorder of melanocyte development characterized by the absence of melanocytes in affected areas of the skin and hair, resulting in distinctive patches of white skin (leukoderma) and white hair (poliosis). It is caused by mutations in the KIT proto-oncogene (most commonly) or the SLUG (SNAI2) gene, which are critical for the migration and survival of melanoblasts from the neural crest during embryonic development. The condition is present from birth and remains stable throughout life. The hallmark feature of piebaldism is a white forelock (a triangular or diamond-shaped depigmented patch of hair on the frontal scalp), which is present in approximately 80-90% of affected individuals. Depigmented patches of skin are typically found on the forehead, anterior trunk (chest and abdomen), and extremities, often with a characteristic midline distribution. These white patches may contain islands of normal or hyperpigmented skin within them. The borders of the depigmented areas frequently show hyperpigmented macules. Importantly, piebaldism does not affect other organ systems — hearing, vision, and neurological function are normal, which distinguishes it from Waardenburg syndrome and other neurocristopathies that also feature pigmentary abnormalities. Piebaldism is a benign condition, and no specific medical treatment is required. However, the depigmented skin lacks melanocytes and is therefore more susceptible to sunburn and potentially to sun-related skin damage, so sun protection is recommended. Cosmetic concerns can be addressed with camouflage cosmetics, and some patients have undergone autologous melanocyte transplantation or skin grafting with variable success. Genetic counseling is appropriate for affected families given the autosomal dominant inheritance pattern with high penetrance but variable expressivity.

Clinical phenotype terms— hover any for plain English:

White forelockHP:0002211Piebald skin depigmentationHP:0007544White eyebrowHP:0002226White eyelashesHP:0002227Abnormal calvaria morphologyHP:0002683
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Piebaldism.

View clinical trials →

No actively recruiting trials found for Piebaldism at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Piebaldism community →

Specialists

10 foundView all specialists →
OP
Olivier Lortholary, MD, PhD
Specialist
PI on 5 active trials
AP
Albert Wolkerstorfer, MD, PhD
Specialist
PI on 1 active trial
MP
Menno A. De Rie, MD, PhD
Specialist
PI on 1 active trial
SP
Sameek Roychowdhury, MD, PhD
COLUMBUS, OH
Specialist
PI on 2 active trials
JM
Joshua D. Milner, MD
NEW YORK, NY
Specialist
PI on 1 active trial
TP
Tara N Heagele, PhD
Specialist
PI on 1 active trial
CP
Cem Akin, M.D., Ph.D.
NORTHVILLE, MI
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Piebaldism.

Search all travel grants →NORD Financial Assistance ↗

Community

Open PiebaldismForum →

No community posts yet. Be the first to share your experience with Piebaldism.

Start the conversation →

Latest news about Piebaldism

No recent news articles for Piebaldism.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Piebaldism

What is Piebaldism?

Piebaldism (also known as partial albinism or piebald trait) is a rare congenital disorder of melanocyte development characterized by the absence of melanocytes in affected areas of the skin and hair, resulting in distinctive patches of white skin (leukoderma) and white hair (poliosis). It is caused by mutations in the KIT proto-oncogene (most commonly) or the SLUG (SNAI2) gene, which are critical for the migration and survival of melanoblasts from the neural crest during embryonic development. The condition is present from birth and remains stable throughout life. The hallmark feature of pie

How is Piebaldism inherited?

Piebaldism follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Piebaldism typically begin?

Typical onset of Piebaldism is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Piebaldism?

10 specialists and care centers treating Piebaldism are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.